Literature DB >> 6746722

Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols.

N Brock, P Hilgard, J Pohl, K Ormstad, S Orrenius.   

Abstract

A number of thiol compounds have been studied with reference to their selective protective action against urotoxic side-effects of oxazaphosphorine cytostatics. The uroprotective capacity is determined exclusively by the pharmacokinetic behavior of the compound. When given PO, all compounds tested were absorbable from the gut. Both thiols and disulfides are rapidly eliminated from the blood, but during their short half-life a number of unknown chemical reactions probably take place to maintain a physiological redox equilibrium. Elimination from the blood plasma occurs via two fundamentally different mechanisms: by distribution throughout the tissues and intracellular uptake or, alternatively, by rapid renal excretion. Most of the compounds tested belong to the first group: N-acetylcysteine, carboxycysteine, disulfiram and its metabolite DDTC, glutathione, WR 2721, etc. Few compounds are quantitatively excreted through the urine: mesna, dimesna, and DA 12. Only these compounds were suitable for selective regional detoxification and for the prevention of oxazaphosphorine-induced urotoxic lesions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6746722     DOI: 10.1007/BF00390979

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  27 in total

1.  [Chemotherapy of cancer. Rationale and possibilities].

Authors:  H DRUCKREY
Journal:  Med Klin       Date:  1961-08-25

2.  [Principles of toxicological methods].

Authors:  H DRUCKREY
Journal:  Arzneimittelforschung       Date:  1957-08

3.  Metabolic activation and hepatotoxicity. Effect of cysteine, N-acetylcysteine, and methionine on glutathione biosynthesis and bromobenzene toxicity in isolated rat hepatocytes.

Authors:  H Thor; P Moldéus; S Orrenius
Journal:  Arch Biochem Biophys       Date:  1979-02       Impact factor: 4.013

Review 4.  Protection against the toxicity of alkylating agents by thiols: the mechanism of protection and its relevance to cancer chemotherapy. A review.

Authors:  T A Connors
Journal:  Eur J Cancer       Date:  1966-12       Impact factor: 9.162

5.  Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds.

Authors:  N Brock; J Pohl; J Stekar
Journal:  Eur J Cancer Clin Oncol       Date:  1981-11

6.  Effect of disulfiram on cyclophosphamide toxicity: a clinical trial.

Authors:  W B Ershler; M P Hacker; R A Newman; J A Stewart; R L Gamelli; I H Krakoff
Journal:  Cancer Treat Rep       Date:  1983-12

7.  Prophylaxis of haemorrhagic cystitis due to cyclophosphamide-conditioning for bone marrow transplantation.

Authors:  H Link; V Neef; D Niethammer; K Wilms
Journal:  Blut       Date:  1981-11

8.  Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria.

Authors:  M Slavik; J H Saiers
Journal:  Semin Oncol       Date:  1983-03       Impact factor: 4.929

9.  The control of ifosfamide-induced hematuria with N-acetylcysteine in patients with advanced carcinoma of the lung.

Authors:  L R Morgan; P J Donley; E F Harrison; H L Hunter
Journal:  Semin Oncol       Date:  1982-12       Impact factor: 4.929

10.  Effect of disulfiram (tetraethylthiuram disulfide) amd diethyldithiocarbamate on the bladder toxicity and antitumor activity of cyclophosphamide in mice.

Authors:  M P Hacker; W B Ershler; R A Newman; R L Gamelli
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

View more
  14 in total

1.  Analysis of acrolein-derived 1,N2-propanodeoxyguanosine adducts in human leukocyte DNA from smokers and nonsmokers.

Authors:  Siyi Zhang; Silvia Balbo; Mingyao Wang; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2010-11-22       Impact factor: 3.739

2.  The stability of mesna in beverages and syrup for oral administration.

Authors:  M P Goren; B A Lyman; J T Li
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide.

Authors:  T Wagner; M Zink; G Schwieder
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

4.  Cause and prevention of mafosfamide-induced venous pain.

Authors:  P Hilgard; J Pohl
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

Review 5.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.

Authors:  L H Einhorn
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.

Authors:  N Brock
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

Review 8.  The role of active metabolites in drug toxicity.

Authors:  M Pirmohamed; N R Kitteringham; B K Park
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

9.  L-cysteine prodrug protects against cyclophosphamide urotoxicity without compromising therapeutic activity.

Authors:  J C Roberts; D J Francetic; R T Zera
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 10.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.